

## Data Sharing Statement

<b>Article Info</b>	<a href="http://dx.doi.org/10.21037/jgo-20-350">http://dx.doi.org/10.21037/jgo-20-350</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Study protocol, Stastical Analysis plan, Analytic code, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Three years within the publication date, since the technique or survival date may be updated over time.
7	To whom will you share the data?	Medical oncologist and surgeons who are interested in studies of Colorectal cancer.
8	For what type of analysis or purpose?	For analysis to evaluate the efficacy of modified bevacizumab-XELOX therapy in patients with Stage IV recurrent or non-resectable colorectal cancer.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: <a href="mailto:daiki66.d@gmail.com">daiki66.d@gmail.com</a>
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.